Treatment of Freckles by Intradermal Tranexamic Acid Versus Q Switched KTP Laser.
NCT ID: NCT03885895
Last Updated: 2019-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
30 participants
INTERVENTIONAL
2019-01-15
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tranexamic Acid vs. Combination With Fractional Carbon Dioxide Laser in Melasma
NCT03899233
Tranexamic Acid in Treatment of Facial Erythema
NCT05897918
Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma.
NCT05911698
Comparison of Intralesional Tranexamic Acid and Platelets Rich Plasma in the Treatment of Melasma
NCT05884151
Tranexamic Acid vs Fractional CO2 Laser in Post-acne Hyperpigmentation
NCT03765021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The other side of the face will be assigned to TXA intradermal microinjection in the same session using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on freckles area at.
The sessions of TXA will be every 2 weeks for 2 months.
Postoperatively, topical antibiotic ointment and steriod will be applied. Sunscreen then applied until the next treatment in order to minimize reactive hyperpigmentations.
Follow up after treatment monthly for 2 month.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with freckles (one side of the face)
one randomized side of the face will be treated by Intradermal Tranexamic acid
Tranexamic Acid Injectable Product
Ampoules used for intradermal injection
Participants with freckles (other side of the face)
other side will be treated by Q switched KTP laser
Q switched KTP (532nm)
LASER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tranexamic Acid Injectable Product
Ampoules used for intradermal injection
Q switched KTP (532nm)
LASER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age group \> 18years old.
Exclusion Criteria
* Keloid and scarring tendancy
* Usage of invasive or semi invasive procedures for treatment of freckles such as chemical peeling , dermaroller..etc. 2 months prior to the study.
* Oral Isotretinoin 6 months prior to the study.
* Active herpetic lesions.
* Any concurrent active skin disease within the treated area.
* Photosensitive skin conditions such as systemic lupus erythematous.
* History of delayed wound healing.
* Bleeding diathesis.
* Medical conditions such as autoimmune diseases.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rana F Hilal, MD
Lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr El Ainy university hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EgyFreckles
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.